Drug intelligence / Profile preview

TQH2929

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

TQH2929 is a novel monoclonal antibody under development for the treatment of psoriasis, including generalized pustular psoriasis (GPP). The drug is being evaluated primarily for its safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in both healthy adults and patients with GPP. While the precise mechanism of action has not been publicly disclosed as of June 2025, it is classified as an antipsoriatic monoclonal antibody. Clinical trials are ongoing in China to assess its potential benefits in immune-mediated skin diseases[1][2][3][4].

Other names: TQH2929TQH-2929TQH 2929

Beyond the preview

Go deeper on TQH2929.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQH2929.

Explore the full profile